Akoya Biosciences, Inc. (NASDAQ: AKYA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock, down previously from $4.00.
LowReport
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock, down previously from $4.00.
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $6.00 to $3.50. They now have a "buy" rating on the stock.
MediumReport
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $6.00 to $3.50. They now have a "buy" rating on the stock.
Akoya Biosciences, Inc. (NASDAQ: AKYA) was downgraded by analysts at Craig Hallum from a "buy" rating to a "hold" rating. They now have a $5.00 price target on the stock, down previously from $7.00.
MediumReport
Akoya Biosciences, Inc. (NASDAQ: AKYA) was downgraded by analysts at Craig Hallum from a "buy" rating to a "hold" rating. They now have a $5.00 price target on the stock, down previously from $7.00.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: